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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not cooling
therapy improves functional mobility in heatsensitive adults diagnosed with MS.
STUDY DESIGN: Systematic review of three randomized controlled trials published between
2007 and 2011, all in the English language.
DATA SOURCES: Three randomized controlled trials were found using the PubMed/MEDLINE
database.
OUTCOMES MEASURED: Functional mobility as measured by the Multiple Sclerosis
Functional Composite (MSFC), postural control, exercise duration, walking speed, and timed up
and go examinations.
RESULTS: In one study, MeyerHeim, et al. demonstrated significant improvements with the
experimental intervention on the 25foot walk, 9hole peg test, as well as the total MSFC, and no
significant different on tests of postural sway and knee spasticity. In terms of exercise duration,
Grahn, et al. found a significant improvement of 33% increase with cooling therapy. Finally, the
study by Reynolds, et al. showed an improvement on the 6minute walk test when comparing
true cooling to the other tested conditions; on the 25foot walk test and the timed up and go, true
cooling was not associated with a significant improvement with regard to the other conditions.
CONCLUSIONS: The reviewed studies, representing the best evidence currently available,
suggest the efficacy of cooling therapy as a welltolerated method for improving functional
mobility in heatsensitive adults diagnosed with multiple sclerosis.
KEY WORDS: cooling, multiple sclerosis
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INTRODUCTION
Multiple sclerosis (MS) refers to a condition in which there is an immunemediated
attack on the central nervous system (CNS). This attack damages the myelin on the neurons and
causes sclerosis (scar tissue) that disrupts neural signal transmission.1 The constellation of
demyelinated neurons, degeneration, and sclerosis forms histopathologically characteristic
inflammatory plaques.2 This paper evaluates three randomized controlled trials (RCTs)
comparing the efficacy of cooling therapy to placebo for improving functional mobility in adults
with MS.
While the prevalence of MS has not been definitely established, it is thought to affect
400,000 people in the U.S. and 2.3 million globally.3 The symptoms of fatigue, spasticity, and
heatsensitivity are interrelated and have a predominant role in determining the impact of MS on
patients’ activities of daily living.4 Additionally, the disease presents a financial burden for
patients and for society as a whole. The total cost of MS for the average patient is estimated to be
$8528−$54,244 annually, and the condition costs the United States approximately $28 billion per
year.5 In fact, due to prescription drug costs and to the early onset of the disease, MS is the
second costliest chronic condition (following congestive heart failure).5
The etiology of MS remains elusive; various triggers, such as viruses and environmental
factors with coexisting immunodeficiency, are supported in the literature.2 While the symptoms
and disease course in MS vary on an individual basis, patients with relapsingremitting multiple
sclerosis (RRMS) are known to have elevated body temperature, even at rest.1 In these patients,
this state is associated with fatigue (general and physical), a phenomenon originally described by
Wilhelm Uhthoff.6
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Treatment of MS can include both symptomatic and diseasemodifying components. The
approach to therapy and specific medications chosen depend on the clinical picture as well as on
the patient’s preferences and input. Symptomatic treatment may include SSRIs (depression),
muscle relaxants (spasticity), and anticholinergic agents (bladder urgency). Addressing the
psychosocial impact of the disease is an essential component. Various diseasemodifying
treatments are approved for MS. These include interferons (e.g. IFNß1b [Betaseron]),
immunomodulators (e.g. glatiramer acetate [Copaxone]), and monoclonal antibodies (e.g.
natalizumab [Tysabri]).7
Because symptomatic treatment does not, as a rule, affect the course of the disease,
patients may reasonably feel that potential adverse effects associated with these measures
outweigh their benefits.7 Furthermore, it seems logical that therapies capable of ameliorating
symptoms without negatively impacting quality of life would be desirable for patients.
Since the observations of Uhthoff in 1890, exercise has been associated with transient
worsening of MS symptoms in most patients (up to 80%). The etiology behind this exacerbation
was traced to hyperthermia several decades ago.8 Despite this history, the efficacy of cooling
therapy in symptomatic relief has not been firmly established in the literature. While cooling
therapy does not offer disease modification, it may have promise as a safe method of alleviating
symptoms and encouraging healthpromoting behaviors such as aerobic exercise. Additionally,
its implementation would underscore the value of the patient’s subjective experience of their
disease.
OBJECTIVE
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The objective of this selective EBM review is to determine whether or not cooling
therapy improves functional mobility in heatsensitive adults diagnosed with MS.
METHODS
Three randomized controlled trials were used in this review. Adults with heatsensitive
multiple sclerosis comprise the population in the studies used. The experimental intervention in
each study was a form of cooling therapy, although each used a different device to achieve
cooling. One study used bilateral thighcuffs that used fluid evaporation to remove body heat.9
Another employed an elastic wrist sleeve with a vacuum pump to create a negative
(subatmospheric) pressure gradient inside the chamber.10 In the third study, a specialized hood
used circulating fluid to conduct heat away from the participant’s head and neck.11 This
intervention was compared to a control, consisting of either an absence of cooling or sham
cooling (in which the participants were fitted with a device they were told was removing body
heat). The outcome for all participants was one or more objective measurements of functional
capability.
All articles reviewed herein were published in the English language and in peerreviewed
journals. A PubMed search was performed using the keywords cooling and multiple sclerosis.
Articles were selected based on relevance to the aforementioned objective and on whether the
measured outcome was patientoriented rather than diseaseoriented. The inclusion criteria
consisted of RCTs published no earlier than 1999. Studies in the chosen articles excluded those
younger than 18 years of age, those with relevant concomitant conditions (e.g. infections,
pregnancy), and those with a recent MS exacerbation or relapse. Reported statistics were
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pvalues, paired ttest, and one and twoway analysis of variance (ANOVA). Table 1
summarizes the demographics of each study.
Table 1 – Demographics & Characteristics of Included Studies
Study

Meyer
Heim
(2007)9

Grahn
(2008)10

Reynolds
(2011)11

Age
(yrs)

Inclusion
Criteria

Type

n

RCT

Clinically
48.7
20
definite MS
(2766)
Heatsensitivity

RCT

Diagnosis of MS
History of
heatsensitivity
50.8
12
Regular exercise
(4263)
program
Ambulates
independently

RCT

6

41.3 ±
7.3

Definite MS
Heatsensitivity

Exclusion
Criteria
EDSS >6.5
Infections/fever,
relapse within 3
mos
Use of steroids

Failure to meet
inclusion criteria

Use of certain
medications*
Participating in
another clinical
trial
Pregnancy
Another neural
or muscular
disease
Exacerbation
within the past
month

With
drawals

Interven
tions

0

Cooling
therapy
(thighcuff
cooling
garments)

2

Cooling
therapy
(one hand
in heat
extraction
device)

0

Cooling
therapy
(head and
neck
cooling
device)

*antihypertensive, vasoactive or diuretic drugs
OUTCOMES MEASURED
MeyerHeim, et al., in their singleblinded balanced crossover study, compared each
participant’s performance on a number of functional examinations with activated thighcuff
cooling to their performance with sham (inactivated) cooling.9 These examinations included the
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MS functional composite (MSFC)(consisting of walking capacity, manual dexterity, and
cognition) as well as in terms of postural control, knee spasticity (Modified Ashworth Scale),
muscle strength of foot dorsal flexion, knee flexion (McMesin Pull Gauge), and grip strength
(Jamar dynamometer).
In a similar study using randomized paired trials, Grahn, et al. measured their subjects’
exercise duration on a standardized treadmill protocol with the stop criteria of symptom
exacerbation and subjective fatigue.10 Under this protocol, the speed and slope on the treadmill
were alternately increased by consistent increments at three minute intervals. A baseline
assessment (without cooling) was completed as a control, and one or more experimental trials
with cooling via wrist cuff device were completed two to seven days after the previous trial.
Lastly, Reynolds, et al. conducted a doubleblinded crossover study in which participants
underwent a battery of tests three times under different conditions: true cooling via specialized
hood, sham cooling, and no cooling; the participants were told that they would undergo two
cooling trials in order to blind them to the presence of sham cooling.11 The tests of functional
mobility included in this battery were the sixminute walk test, the 25foot walk test, and the
timed up and go test.11 The performance measurements (with parameters determined by the
nature of each test) were then compared across the three conditions.
RESULTS
Three RCTs compared functional mobility with and without a cooling stimulus in
heatsensitive adults diagnosed with MS. MeyerHeim, et al. studied 20 adults from 27 to 66
years of age (mean 48.7 years). Each participant completed paired trials, one with activated
cooling and one with inactivated sham cooling as a control. The study was singleblinded; the
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participants, but not the researchers, were blinded to which of the two trials was experimental.
During each trial, the participants underwent a number of tests of functional mobility, the results
of which are continuous data. No participants were said to be lost to followup. Tympanic
temperature was not significantly altered between the active and sham cooling trials (Table 2).
Skin temperature was ~4°C lower during the active cooling trials; the authors do not comment on
the significance of this deviation. Significant improvement was noted in the 25foot walk,
ninehole peg test (a test of manual dexterity), and the total MSFC (p < 0.05). According to the
participants, the cooling device was without adverse effects.
Table 2 – MeyerHeim, et al.: Treatment vs. Control Trials
Outcome measure

Active cooling

Sham control

P value

Tympanic temp. change (°C, SD)

– 0.092 (0.25)

– 0.047 (0.22)

0.126

MSFC (zscore, SD)
T25FW (s mean, SD)
9HPT (s mean left/right) (median IQR)
PASAT3 (no. correct mean, SD)

0.952 (0.88)
14.2 (10.8)
29.5 (9.6)
40.4 (16.5)

0.723 (1.11)
18.0 (17.3)
34.3 (17.1)
39.4 (15.9)

0.017
0.035
0.012
0.747

Postural sway, 30 s* (cm/s, SD) (mean
displacement velocity)
Eyes open
Eyes closed

2.24 (0.97)
3.98 (1.72)

2.53 (1.05)
4.39 (2.15)

0.65
0.55

1.08 (1.0)

1.08 (0.9)

0.835

Spasticity Knee (Modified Ashworth
Scale) mean left/right (SD)

T25FW, Timed 25Foot Walk; 9HPT, NineHole Peg Test; PASAT3, Paced Auditory Serial
Addition Test with a threesecond interstimulus interval
*10 s of the recording have been omitted systematically to avoid disturbance from delayed
stabilization of the recording equipment after the person stepped onto the force plate
Grahn, et al. studied 12 adults from 42 to 63 years of age (mean 50.8 years). Two
subjects were lost to followup as they withdrew from the study due to selfreported relapse. As
above, each participant completed paired trials. In this study, one trial was with cooling and the
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other was without cooling; no sham cooling condition was used. Neither the participant nor the
researchers were blinded to the presence or absence of cooling during each trial. During each
trial, participants exercised until reaching a stop criterion (subjective fatigue or symptom
exacerbation), and the duration of exercise was recorded as continuous data. With the studied
intervention, exercise duration increased significantly as a group (p < 0.003, paired ttest)(Table
3) and improved for each subject. Body temperature was not measured and therefore could not
be compared between the cooling and control trials. Adverse effects of cooling were not
explicitly reported. However, a change in usual symptoms was reported by “several” subjects,
who stated that, during cooling, their symptoms occurred in waves rather than as progressive
fatigue. One participant reported a “tingling” in the legs rather than the “cloudy” feeling he
typically experiences during exercise.
Table 3 – Grahn, et al.: Treadmill Speed & Slope in Treatment vs. Control Trials
Subject

Speeda
(Km/h)

Slopea
(%)

Number of
paired
trials

1

4.8

5–6

2

0.8

3

Exercise duration (min)
Control

Cooling

Cooling
effect
(ratio)

3

17.2

22.9

1.34

0

1

20.0

32.0

1.60

4.0

5–6

3

20.7

22.1

1.07

4

1.3

0

1

25.0

28.3

1.13

5

3.2 – 4.8

6

4

36.4

44.8

1.23

6

4.8

7 – 8.5

3

37.4

49.8

1.33

7

4.0

6–7

5

38.4

51.6

1.34

8

2.4

0

2

39.8

43.2

1.09

9

3.2

0

2

39.9

67.5

1.69

10

3.2

5.5 – 6

2

42.3

65.8

1.55
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Groupb
a
b

Mean ± Standard Deviation

31.7 ± 9.8

42.8 ± 16.4 1.35 ± 0.22

Slopes and speeds of the treadmill were adjusted between sets of paired trials.
P < 0.01, paired ttest
Reynolds, et al. studied six adults with a mean age of 41.3 ± 7.3 years; while all

participants in this study were female, the authors report that this gender distribution was not by
design. No subjects were reported as lost to followup. Participants completed a battery of tests
under three conditions: true cooling, sham cooling, and no cooling. A physiotherapist conducted
the battery of tests and was blinded to under which condition each trial was performed; the
participants were also blinded to true and sham cooling. After resting for 20 minutes, participants
were fitted with a cooling hood for 60 minutes, regardless of the presence of actual cooling or
not. Following another rest period for 10 minutes, subjects began the tests. All data obtained
were continuous. Body temperature (measured rectally) was found to be 0.37°C lower in the true
cooling condition visàvis sham and no cooling (p < 0.01). ANOVA was performed on the trials
to determine statistical significance of outcomes measured (Table 4). In terms of the tests of
functional mobility, a significant difference (p = 0.036) was found between true cooling and
sham or no cooling on the sixminute walk test. Comparing true and sham cooling to the no
cooling condition, there was also a significant improvement (p = 0.004) on the timed up and go.
No significant difference was found between the trials on the 25foot walk test. Participants did
not experience any side effects to the experimental intervention.
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Table 4 – Reynolds, et al.: Summary of Mean (SD) Performance Measurements &
Statistical Comparisons Across the No, Sham, and True Cooling Conditions

†

True Cooling

Sham Cooling

No Cooling

25foot walk test (seconds)
F = 2.462 & P = 0.13

5.80 (1.54)

5.82 (1.54)

6.10 (1.61)

Timed up and go (seconds)
F = 11.21 & P = 0.0036

11.53 (4.63)†

12.03 (5.23)†

12.96 (5.34)

6minute walk test (meters)
F = 4.731 & P = 0.036

459.1 (116.5)††

437.7 (112.5)

414.3 (96.4)

significant difference from no cooling
significant difference from both no cooling and sham cooling

††

DISCUSSION
Because cooling therapy did not elicit any adverse effects in any of the three studies
included in this review, it appears to be a welltolerated approach to managing symptoms of MS.
However, longterm evaluation of its safety cannot be inferred from these studies, as all
participants were evaluated and surveyed soon after the experimental intervention was
completed. Additionally, the three studies used different devices to achieve a cooling effect; still
more devices are commercially available, including cooling vests.12 The safety of one device
should not be understood as representing the safety of another. For example, some devices may
reach significantly lower temperatures that could potentially cause some type of hypothermic
injury. Finally, specific parameters (e.g. indications, contraindications) for the use of cooling
therapy would ideally be developed before its widespread clinical application.
One common barrier with which patients are faced when starting a nonstandard therapy
for a given condition is payment, as many patients are unable to cover their medical costs
without financial assistance. The Multiple Sclerosis Association of America (MSAA) currently
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offers “cooling and assistive equipment” (including cooling vests) for people diagnosed with MS
who complete an online application and meet household income requirements.12 Health
insurance companies may not pay for cooling therapy, considering it experimental or not covered
by certain specific coverage plans.
There are several limitations of the studies included in this review, some of which were
explicitly mentioned within the respective text. Only Reynolds, et al. used a threearmed
approach to evaluate differences between true cooling, sham cooling, and no cooling. In the
study by Grahn, et al., failing to blind participants (as well as researchers) to their testing
condition (i.e. the absence of sham cooling trials) introduces the confounding factor of a placebo
effect. MeyerHeim, et al. used a singleblinded approach in which the assessment raters were
aware of the cooling condition (i.e. true or sham) of each trial, and it cannot be ruled out that this
knowledge impacted the results of the study. For example, the raters could have subtly and
unintentionally encouraged participants when they were known to be under the experimental
condition.
Another challenge associated with blinding in this nature of research is that, in the study
by MeyerHeim, et al., the vast majority of participants (90%) were able to identify the sham
cooling condition correctly. Reynolds, et al. addressed this issue by intermittently running cold
fluid through the cooling hood during the sham cooling trials; this was reported as conveying a
sensation of cold without actually affecting body temperature. However, they did not indicate
whether participants were unable to discern sham from true cooling.
A limitation shared by all studies reviewed herein is small sample size (n1 = 20, n2 = 12,
n3 = 6). Grahn, et al. addressed this limitation through repeated trials with the same participants.
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In their trial of 12 subjects (less 2 who were lost to followup), 88 trials were completed, with 26
data sets meeting the criteria for paired trials. As more data are gathered on cooling therapy with
presumably promising results for MS, it would strengthen the body of evidence for studies to
progressively enlarge their sample sizes.
This review of cooling therapy for heatsensitive adults diagnosed with MS is inherently
limited in itself. First, covering more than three studies would have been outside its established
scope. Furthermore, only RCTs from a single database were included, which may not necessarily
be representative of the entire current body of research. Other forms of research (e.g. case
studies) were excluded due to the associated less rigorous standards and higher potential for
confounding factors. Finally, while studies published prior to 1999 may have been informative,
they were excluded in the interest of conducting an uptodate evaluation.
CONCLUSION
Based on the best currently available evidence, cooling therapy appears to be effective in
improving functional mobility in heatsensitive adults with a diagnosis of MS. Future studies are
needed to determine the optimum protocol (i.e. the ideal temperature, timing of cooling, etc.) and
device (e.g. thighcuff vs. cooling hood vs. wrist sleeve) for this therapy. Alternate methods of
blinding would benefit further research in order to control for placebo. To achieve this end,
Grahn, et al. suggest experimental use of nerve blocks to eliminate cutaneous afferent input,
following establishment of cooling therapy as effective. This intervention seems appropriate now
in light of the demonstrated shortcomings of sham cooling for blinding.
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